GlassScriptPhysician profile
Thomas L Pitts
NPI 1730146671
$12,197.23
in general payments reported to CMS, 2019-2025
44 companies · $39.85 in 2025
The $39.85 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,347 · 2020: $2,394 · 2021: $2,712 · 2022: $2,362 · 2023: $1,342 · 2025: $39.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $34.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.03 |
| Education | $34.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,650.84 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,482.06 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,336.42 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $952.95 | 2019-2023 | Mounjaro, Trulicity |
| Mannkind Corporation | $838.91 | 2019-2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $741.46 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $709.87 | 2019-2023 | Steglatro, Steglujan |
| Abbvie INC. | $489.24 | 2019-2023 | |
| Dexcom, INC. | $401.22 | 2019-2023 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $365.55 | 2019-2023 | Korlym |
| Amgen INC. | $329.37 | 2019-2025 | Tepezza, Evenity, Prolia |
| Ibsa Pharma INC. | $269.09 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $251.82 | 2019-2020 | |
| Intuity Medical INC | $238.47 | 2022 | |
| Medtronic, INC. | $231.42 | 2021 |
Show all 42 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.